UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

Journal of hepatology, 2019-05, Vol.70 (5), p.1019-1023

2019

Link zum Volltext

Verfügbarkeit prüfen

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry

PloS one, 2022-06, Vol.17 (6), p.e0264741-e0264741

2022

Link zum Volltext

Verfügbarkeit prüfen

Real‐world effectiveness of sofosbuvir‐based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO‐03)

Journal of medical virology, 2018-02, Vol.90 (2), p.304-312

2018

Link zum Volltext

Verfügbarkeit prüfen

Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R)

Biomedicines, 2021-10, Vol.9 (10), p.1495

2021

Link zum Volltext

Verfügbarkeit prüfen

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

Hepatology communications, 2022-09, Vol.6 (9), p.2488-2495

2022

Link zum Volltext

Verfügbarkeit prüfen

A not so easy genotype—striking regional differences in SOF/RBV treatment responses in HCV GT2

Liver international, 2017-08, Vol.37 (8), p.1253-1254

2017

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

The New England journal of medicine, 2015-12, Vol.373 (27), p.2599-2607

2015

Link zum Volltext

Verfügbarkeit prüfen

Direct‐acting antiviral treatment of chronic HCV‐infected patients on opioid substitution therapy: Still a concern in clinical practice?

Addiction (Abingdon, England), 2018-05, Vol.113 (5), p.868-882

2018

Link zum Volltext

Verfügbarkeit prüfen

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

Journal of hepatology, 2018-04, Vol.68 (4), p.663-671

2018

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs

Clinical infectious diseases, 2013-08, Vol.57 (suppl 2), p.S129-S137

2013

Link zum Volltext

Verfügbarkeit prüfen

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real‐world data from the German Hepatitis C‐Registry

Liver international, 2021-05, Vol.41 (5), p.949-955

2021

Link zum Volltext

Verfügbarkeit prüfen

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

Liver international, 2020-03, Vol.40 (3), p.539-548

2020

Link zum Volltext

Verfügbarkeit prüfen

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R)

Journal of viral hepatitis, 2021-10, Vol.28 (10), p.1474-1483

2021

Link zum Volltext

Verfügbarkeit prüfen

Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus–Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis

The Journal of infectious diseases, 2019-10, Vol.220 (10), p.1635-1644

2019

Link zum Volltext

Verfügbarkeit prüfen

Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)

Zeitschrift fur Gastroenterologie, 2023-05, Vol.61 (5), p.489

2023

Link zum Volltext

Verfügbarkeit prüfen

Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”

Journal of hepatology, 2017-08, Vol.67 (2), p.420-422

2017

Link zum Volltext

Verfügbarkeit prüfen

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Advances in therapy, 2020-09, Vol.37 (9), p.4033-4042

2020

Link zum Volltext

Verfügbarkeit prüfen

Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral therapy—Results from the German Hepatitis C‐Registry

Journal of viral hepatitis, 2020-07, Vol.27 (7), p.690-698

2020

Link zum Volltext

Verfügbarkeit prüfen

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials

Liver international, 2017-02, Vol.37 (2), p.205-211

2017

Link zum Volltext

Verfügbarkeit prüfen

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

Journal of hepatology, 2020-03, Vol.72 (3), p.431-440

2020

Link zum Volltext

Verfügbarkeit prüfen

Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry

Journal of viral hepatitis, 2021-11, Vol.28 (11), p.1660-1664

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

Liver international, 2018-11, Vol.38 (11), p.1906-1910

2018

Link zum Volltext

Verfügbarkeit prüfen

A decrease in hepatitis C virus RNA to undetectable levels in chronic hepatitis C patients after PegIFNα + RVB or sofosbuvir + NS5A inhibitor treatment is associated with decreased insulin resistance and persistent oxidative stress

Archives of virology, 2020-12, Vol.165 (12), p.2759-2766

2020

Link zum Volltext

Verfügbarkeit prüfen

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment

Journal of viral hepatitis, 2019-02, Vol.26 (2), p.224-230

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 31

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

ThemaHepatitis C

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(31)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(29)
Life Sciences & Biomedicine
(28)
Gastroenterology & Hepatology
(18)
Humans
(17)
Patients
(16)
Hepatitis
(15)
Infectious Diseases
(12)
Adult
(11)
Antiviral Agents - Therapeutic Use
(11)
Interferon
(11)
Male
(11)
Chronic Infection
(10)
Cirrhosis
(10)
Female
(10)
Genotypes
(10)
Hepatitis C, Chronic - Drug Therapy
(10)
Antiviral Agents
(9)
Hcv
(9)
Infections
(9)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry

Real‐world effectiveness of sofosbuvir‐based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO‐03)

Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R)

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

A not so easy genotype—striking regional differences in SOF/RBV treatment responses in HCV GT2

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

Direct‐acting antiviral treatment of chronic HCV‐infected patients on opioid substitution therapy: Still a concern in clinical practice?

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real‐world data from the German Hepatitis C‐Registry

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R)

Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus–Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis

Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)

Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral therapy—Results from the German Hepatitis C‐Registry

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

A decrease in hepatitis C virus RNA to undetectable levels in chronic hepatitis C patients after PegIFNα + RVB or sofosbuvir + NS5A inhibitor treatment is associated with decreased insulin resistance and persistent oxidative stress

Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance‐associated substitutions

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment

Aktive Filter

Suchergebnisse filtern